BioAge Labs, Inc. (BIOA) AI Stock Analysis

• Market Cap: $141.61M
• Dividend Yield: N/A
• Average Volume (3M): 337.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 60
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.05
• Shares Outstanding: 35,850,037
• 10 Day Avg. Volume: 255,069
• 30 Day Avg. Volume: 337,184
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 2.73
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.67
• Price Target Upside: 43.54% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

BioAge Labs, Inc. is facing critical financial difficulties, characterized by no revenue generation, increasing losses, and dependence on external financing. The technical indicators suggest a bearish trend, and the lack of valuation metrics such as P/E ratio and dividend yield complicates valuation. These factors collectively reflect a weak overall stock performance.

Positive Factors

Financial Stability

BioAge ended the first quarter with $335.1 million in cash, and the company's balance sheet is expected to fund operations through at least 2029.

Pipeline Advancement

BGE-102 continues to advance towards Phase 1 SAD data, indicating progress in the company's pipeline.

Negative Factors

Clinical Risks

There is a lack of robust clinical data to support the hypothesis of NLRP3 inhibition as a therapeutic weight management strategy.

Clinical Setback

The discontinuation of the lead azelaprag program due to the emergence of liver transaminitis is a notable update.

BioAge Labs, Inc. Business Overview & Revenue Model

Company Description

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

How the Company Makes Money

BioAge Labs, Inc. generates revenue primarily through partnerships and collaborations with pharmaceutical companies, as well as through research grants and funding. The company engages in strategic alliances to co-develop and commercialize its therapeutic candidates, which allows it to share development costs and potential profits. Additionally, BioAge may receive milestone payments and royalties from its partners as its drug candidates progress through clinical trials and, if successful, reach the market. The company may also rely on venture capital investments and public or private offerings to fund its research and development activities.

BioAge Labs, Inc. Financial Statement Overview

Summary

BioAge Labs, Inc. faces significant financial challenges, with no revenue generation and increasing losses impacting profitability. While the balance sheet has improved due to recent financing activities, the company's reliance on external funds and negative cash flows suggest ongoing financial instability. The company needs to address its revenue generation capabilities to improve its financial health.

Income Statement

BioAge Labs, Inc. has not generated any revenue over the past three years, impacting its ability to achieve positive profit margins. The company is experiencing increasing losses, as reflected in the negative EBIT and net income figures. This lack of revenue generation and increasing losses are significant concerns for the company's financial health.

Balance Sheet

The company's debt-to-equity position has improved significantly, transitioning from negative equity to a positive equity position in 2024, driven by increased financing activities. Despite this improvement, the company still carries some debt, which poses a risk. The equity ratio has improved to 90%, indicating a stronger balance sheet, but the company's reliance on external financing remains a concern.

Cash Flow

BioAge Labs, Inc. has been raising substantial funds, as seen from the positive financing cash flow. However, the company is still burning cash, with negative operating and free cash flows. The free cash flow growth rate remains negative, indicating ongoing operational cash challenges. The company's ability to sustain operations relies heavily on external financing, posing sustainability risks.

Breakdown
Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00
	EBIT
-78.19M	-48.40M	-39.97M
	EBITDA
-78.19M	-55.90M	-39.35M
	Net Income Common Stockholders
-71.11M	-63.85M	-39.72M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
354.35M	21.64M	27.64M
	Total Assets
358.23M	25.92M	28.43M
	Total Debt
6.20M	53.25M	2.47M
	Net Debt
-348.15M	31.61M	-25.18M
	Total Liabilities
35.11M	199.32M	140.99M
	Stockholders Equity
323.13M	-173.40M	-112.56M
Cash Flow		Free Cash Flow
-51.89M	-37.53M	-36.28M
	Operating Cash Flow
-51.52M	-37.36M	-36.18M
	Investing Cash Flow
-366.00K	-266.00K	-103.00K
	Financing Cash Flow
381.20M	34.94M	2.50M

BioAge Labs, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DERM	58 Neutral	$150.29M	―	-72.60%	―	-29.11%	-219.44%
IRWD	53 Neutral	$149.98M	85.74	-8.02%	―	-20.63%	―
Sector *	52 Neutral	$5.24B	3.76	-41.88%	2.85%	17.01%	0.78%
ASRT	48 Neutral	$58.42M	―	-16.66%	―	-17.83%	94.26%
ESPR	46 Neutral	$215.98M	―	23.44%	―	12.99%	17.78%
OPTN	44 Neutral	$94.99M	―	75.79%	―	10.19%	44.46%
BIOA	33 Underperform	$141.61M	―	36.83%	―	―	―